In major clinical trials, such as the landmark STEP 1 trial published in the New England Journal of Medicine , a once-weekly injection of semaglutide 2.4 mg resulted in an average body weight reduction of roughly 14.9% over 68 weeks
KLOW sits within our broader peptide therapy program and is available across our Florida locations, supervised from your first evaluation through follow-up
Were it not for their efforts we might not have this unprecedented treatment for obesity, which has now unlocked many other potential clinical applications
GLP-1s not tied to suicide, self-harm According to Peter Ueda, MD, PhD , an assistant professor at Karolinska Institute in Sweden, and colleagues, the effect of GLP-1 receptor agonists on suicidality is plausible becausre the drugs have been shown to cross the blood-brain barrier. However, they also pointed out how some have hypothesized that GLP-1 receptor agonists could protect against mental illness like depression
Peptides for neuropathy represent a genuine frontier in nerve repair research, with mechanisms that conventional treatments simply do not address
Auckland: Auckland University of Technology (2023)
